This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Kisqali
  • /
  • Study of Efficacy and Safety of LEE011 in Postmeno...
Clinical trial

Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2)

Read time: 3 mins
Last updated:17th Dec 2013
Identifier: NCT01958021

Brief Summary:
This is a multi-center, randomized, double-blinded, placebo controlled trial.

Detailed Description:
The primary purpose of this study was to assess the efficacy of LEE011, as measured by progression free survival (PFS), in postmenopausal women with HR positive, HER2 negative advanced breast cancer who received no prior treatment for advanced disease.


Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 668 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized Double-blind, Placebo-controlled Study of LEE011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
Actual Study Start Date: December 17, 2013
Actual Primary Completion Date: January 29, 2016
Estimated Study Completion Date: August 31, 2021

Arms:
- Experimental:
LEE011 + letrozole
- Placebo Comparator: Placebo + letrozole


Related journal:
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

Category Value
Date last updated at source 2019-07-02
Study type(s) Interventional
Expected enrolment 668
Study start date 2013-12-17
Estimated primary completion date 2016-01-29

View full details